| Literature DB >> 22310602 |
N Nakamura1, H Mikami, H Matsuoka, S Irie, Y Abe, Y Sasatomi, S Ogawara, T Saitoh, M Tanaka.
Abstract
We have used low doses of mizoribine (MZ) or mycophenolate mofetil (MMF) as induction and maintenance immunosuppressants, but since 2009 have employed a high dose of MZ. We reviewed the efficacy and side effects of MZ compared with MMF. It is difficult to compare graft survivals between these periods because of different patient demographics, though the high dose of MZ cohort showed no significant difference from MMF. High doses of MZ serum to prevent acute rejection episodes as the induction and maintenance therapy. MZ controlled with blood concentrations showed less side effects, suggesting that high MZ doses could be safely used for an induction and maintenance antimetabolite.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22310602 DOI： 10.1016/j.transproceed.2011.11.020
Source DB: PubMed Journal: Transplant Proc ISSN： 0041-1345 Impact factor: 1.066